ストックスクリーナーアプリを入手
9.8217
7.42%
0.6617
前日終値:
$9.16
開ける：
$9.33
24時間の取引高:
101.74K
Relative Volume:
0.09
時価総額：
$1.04B
収益：
$247.00M
当期純損益:
$-249.00M
株価収益率:
-3.1785
EPS:
-3.09
ネットキャッシュフロー:
$-267.00M
1週間 パフォーマンス:
+6.26%
1か月 パフォーマンス:
+14.02%
6か月 パフォーマンス:
-26.18%
1年 パフォーマンス:
-32.60%
1日の値動き範囲:
$9.19
$9.89
1週間の範囲:
$9.125
$9.89
52週間の値動き範囲:
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
名前
Arcus Biosciences Inc
セクター
電話
(510) 694-6200
住所
3928 POINT EDEN WAY, HAYWARD, CA
RCUS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
9.83 | 956.14M | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.38 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.48 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.00 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
573.83 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.31 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-26 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | 開始されました | H.C. Wainwright | Neutral |
| 2024-10-08 | 開始されました | Wells Fargo | Overweight |
| 2022-11-18 | 開始されました | BofA Securities | Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2020-11-24 | 開始されました | Berenberg | Buy |
| 2020-11-23 | 開始されました | Evercore ISI | Outperform |
| 2020-04-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-09-27 | 開始されました | Mizuho | Buy |
| 2019-05-24 | 再開されました | Citigroup | Buy |
| 2018-10-09 | 開始されました | Wedbush | Outperform |
| 2018-04-09 | 開始されました | Citigroup | Buy |
| 2018-04-09 | 開始されました | Goldman | Neutral |
| 2018-04-09 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Arcus Biosciences Inc (RCUS) 最新ニュース
Is Arcus Biosciences Inc. a good long term investmentConsistent high-performance stocks - Autocar Professional
Arizona State Retirement System Purchases 5,010 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
What drives Arcus Biosciences Inc. stock priceExceptional gains - jammulinksnews.com
Arcus Biosciences Inc. Stock Analysis and ForecastTriple-digit returns - jammulinksnews.com
What analysts say about Arcus Biosciences Inc. stockExplosive earning power - jammulinksnews.com
Teacher Retirement System of Texas Has $143,000 Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Principal Financial Group Inc. Boosts Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Is Arcus Biosciences Inc. stock a good hedge against inflationFree Stock Investment Discussion Area - Newser
Trend Tracker for (RCUS) - news.stocktradersdaily.com
how arcus biosciences inc. stock performs during market volatilityTrending Stock Alert - Newser
How Arcus Biosciences Inc. stock performs during market volatilitySafe and Smart Investment Picks - Newser
What makes Arcus Biosciences Inc. stock price move sharplyFree Expert Investment Advice - Newser
Why Arcus Biosciences Inc. stock attracts strong analyst attentionElite Stock Shortlist - Newser
Allspring Global Investments Holdings LLC Has $144,000 Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Allspring Global Investments Holdings LLC Purchases 6,453 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Amalgamated Bank Boosts Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus wins FDA orphan status for cancer drug (RCUS:NYSE) - Seeking Alpha
Arcus Biosciences' Investigational Pancreatic Cancer Treatment Gets US FDA Orphan Drug Status - MarketScreener
Arcus Biosciences' Quemliclustat Gets Orphan Drug Status For Pancreatic Cancer - Nasdaq
Arcus' Pancreatic Cancer Drug Gets FDA Orphan Status as Phase 3 Trial Nears Full Enrollment - Stock Titan
Does Arcus Biosciences (NYSE:RCUS) Have A Healthy Balance Sheet? - simplywall.st
Arcus Biosciences' Quemliclustat Receives Orphan Drug Designatio - GuruFocus
Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment - MSN
State of Alaska Department of Revenue Boosts Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | R - GuruFocus
(RCUS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
GAMMA Investing LLC Buys 15,466 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences’ SWOT analysis: promising cancer therapy stock faces pivotal year - Investing.com
Arcus Biosciences Sees Unusually High Options Volume (NYSE:RCUS) - Defense World
Arcus Biosciences Holds Annual Stockholders Meeting - TipRanks
Arcus Biosciences Inc Inc. (RCUS) Price Performance: A Technical Analysis Perspective - investchronicle.com
Positive Signs As Multiple Insiders Buy Arcus Biosciences Stock - simplywall.st
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 7,872 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Cantor Fitzgerald Comments on RCUS FY2026 Earnings - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | RCUS Stock News - GuruFocus
Arcus Biosciences Inc (RCUS) 財務データ
収益
当期純利益
現金流量
EPS
Arcus Biosciences Inc (RCUS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ROSEN TERRY J | Chief Executive Officer |
Feb 27 '25 |
Buy |
10.18 |
19,800 |
201,465 |
2,554,160 |
| GILEAD SCIENCES, INC. | 10% Owner |
Feb 18 '25 |
Buy |
11.00 |
1,363,636 |
14,999,996 |
31,424,760 |
| Goeltz II Robert C. | Chief Financial Officer |
Dec 31 '24 |
Sale |
15.00 |
3,594 |
53,910 |
60,138 |
4.79%
0.24%
大文字化:
|
ボリューム (24 時間):